Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
Dapagliflozin
EQ‐5D index
Heart failure
Quality of life
Symptoms
Visual analogue scale
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
revised:
13
03
2024
received:
29
01
2024
accepted:
13
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores. We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively. Patients reporting higher (better) EQ-5D-5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator-reported (New York Heart Association class) and patient-self-reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N-terminal pro-B-type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ-5D-5L VAS scores had better outcomes: the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72-0.91) in Q2, 0.74 (0.65-0.84) in Q3, and 0.62 (0.54-0.72) in Q4. The risk of each component of the composite outcome, and all-cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ-5D-5L VAS and index scores across the range of ejection fraction. Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation Centre of Research Excellence
ID : RE/18/6/34217
Organisme : Vera Melrose Heart Failure Research Fund
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state‐of‐the‐art review. J Am Coll Cardiol 2020;76:2379–2390. https://doi.org/10.1016/j.jacc.2020.09.542
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA‐HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR‐Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–1424. https://doi.org/10.1056/NEJMoa2022190
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR‐Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. https://doi.org/10.1056/NEJMoa2107038
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655
Zawadzka MM, Grabowski M, Kapłon‐Cieślicka A. Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment. Adv Clin Exp Med 2022;31:1163–1172. https://doi.org/10.17219/acem/149728
Deichl A, Wachter R, Edelmann F. Comorbidities in heart failure with preserved ejection fraction. Herz 2022;47:301–307. https://doi.org/10.1007/s00059‐022‐05123‐9
van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, et al. Co‐morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16:103–111. https://doi.org/10.1002/ejhf.30
Yang M, Kondo T, Adamson C, Butt JH, Abraham WT, Desai AS, et al. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. Eur J Heart Fail 2023;25:1606–1618. https://doi.org/10.1002/ejhf.2962
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al.; FAIR‐HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448. https://doi.org/10.1056/NEJMoa0908355
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al.; STEP‐HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–1084. https://doi.org/10.1056/NEJMoa2306963
Thomas M, Jones PG, Cohen DJ, Suzanne AV, Magnuson EA, Wang K, et al. Predicting the EQ‐5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. Eur Heart J Qual Care Clin Outcomes 2021;7:388–396. https://doi.org/10.1093/ehjqcco/qcab014
Ravera A, Santema BT, Sama IE, Meyer S, Lombardi CM, Carubelli V, et al. Quality of life in men and women with heart failure: Association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. Eur J Heart Fail 2021;23:567–577. https://doi.org/10.1002/ejhf.2154
Jonsson Å, Orwelius L, Dahlstrom U, Kristenson M. Evaluation of the usefulness of EQ‐5D as a patient‐reported outcome measure using the Paretian classification of health change among patients with chronic heart failure. J Patient Rep Outcomes 2020;4:50. https://doi.org/10.1186/s41687‐020‐00216‐7
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L). Qual Life Res 2011;20:1727–1736. https://doi.org/10.1007/s11136‐011‐9903‐x
Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE, et al. Utility‐based quality of life measures in Alzheimer's disease. Qual Life Res 2006;15:631–643. https://doi.org/10.1007/s11136‐005‐4364‐8
Hounsome N, Orrell M, Edwards RT. EQ‐5D as a quality of life measure in people with dementia and their carers: Evidence and key issues. Value Health 2011;14:390–399. https://doi.org/10.1016/j.jval.2010.08.002
Orgeta V, Edwards RT, Hounsome B, Orrell M, Woods B. The use of the EQ‐5D as a measure of health‐related quality of life in people with dementia and their carers. Qual Life Res 2015;24:315–324. https://doi.org/10.1007/s11136‐014‐0770‐0
Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Development of DEMQOL‐U and DEMQOL‐PROXY‐U: Generation of preference‐based indices from DEMQOL and DEMQOL‐PROXY for use in economic evaluation. Health Technol Assess 2013;17:1–140. https://doi.org/10.3310/hta17050
Keetharuth AD, Hussain H, Rowen D, Wailoo A. Assessing the psychometric performance of EQ‐5D‐5L in dementia: A systematic review. Health Qual Life Outcomes 2022;20:139. https://doi.org/10.1186/s12955‐022‐02036‐3
Brooks R. EuroQol: The current state of play. Health Policy 1996;37:53–72. https://doi.org/10.1016/0168‐8510(96)00822‐6
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ‐5D‐5L: Mapping the EQ‐5D‐5L to EQ‐5D‐3L value sets. Value Health 2012;15:708–715. https://doi.org/10.1016/j.jval.2012.02.008
Poór AK, Rencz F, Brodszky V, Gulácsi L, Beretzky Z, Hidvégi B, et al. Measurement properties of the EQ‐5D‐5L compared to the EQ‐5D‐3L in psoriasis patients. Qual Life Res 2017;26:3409–3419. https://doi.org/10.1007/s11136‐017‐1699‐x
Devlin N, Pickard S, Busschbach J. The development of the EQ‐5D‐5L and its value sets. In: Devlin N, Roudijk B, Ludwig K, eds. Value sets for EQ‐5D‐5L: A compendium, Comparative Review & User Guide. Cham: Springer International Publishing; 2022. p1–12.
Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U, Kahan T. Determinants of utility based on the EuroQol five‐dimensional questionnaire in patients with chronic heart failure and their change over time: Results from the Swedish Heart Failure Registry. Value Health 2015;18:439–448. https://doi.org/10.1016/j.jval.2015.02.003
Sepehrvand N, Savu A, Spertus JA, Dyck JRB, Anderson T, Howlett J, et al.; Alberta HEART Investigators. Change of health‐related quality of life over time and its association with patient outcomes in patients with heart failure. J Am Heart Assoc 2020;9:e017278. https://doi.org/10.1161/jaha.120.017278
Kularatna S, Senanayake S, Chen G, Parsonage W. Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to EQ‐5D‐5L in patients with heart failure. Health Qual Life Outcomes 2020;18:115. https://doi.org/10.1186/s12955‐020‐01368‐2
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial. Eur J Heart Fail 2021;23:1217–1225. https://doi.org/10.1002/ejhf.2249
Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail 2022;10:184–197. https://doi.org/10.1016/j.jchf.2021.11.006
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al.; DAPA‐HF Committees and Investigators. A trial to evaluate the effect of the sodium‐glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). Eur J Heart Fail 2019;21:665–675. https://doi.org/10.1002/ejhf.1432
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al.; DAPA‐HF Committees and Investigators. The Dapagliflozin and Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: Baseline characteristics. Eur J Heart Fail 2019;21:1402–1411. https://doi.org/10.1002/ejhf.1548
Hołownia‐Voloskova M, Tarbastaev A, Golicki D. Population norms of health‐related quality of life in Moscow, Russia: The EQ‐5D‐5L‐based survey. Qual Life Res 2021;30:831–840. https://doi.org/10.1007/s11136‐020‐02705‐0
Gallagher AM, Lucas R, Cowie MR. Assessing health‐related quality of life in heart failure patients attending an outpatient clinic: A pragmatic approach. ESC Heart Fail 2019;6:3–9. https://doi.org/10.1002/ehf2.12363
Di Tanna GL, Urbich M, Wirtz HS, Heisen M, Bennison C, Brazier J, et al. Health state utilities of patients with heart failure: A systematic literature review. Pharmacoeconomics 2021;39:211–229. https://doi.org/10.1007/s40273‐020‐00984‐6
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR‐Preserved Trial Study Group. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR‐Preserved trial. Circulation 2021;144:1284–1294. https://doi.org/10.1161/CIRCULATIONAHA.121.056824
Ostrominski JW, Vaduganathan M, Claggett BL, de Boer RA, Desai AS, Dobreanu D, et al. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial. Eur J Heart Fail 2022;24:1892–1901. https://doi.org/10.1002/ejhf.2652
Mullens W, Dauw J, Martens P, Meekers E, Nijst P, Verbrugge FH, et al. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline characteristics. Eur J Heart Fail 2022;24:1601–1610. https://doi.org/10.1002/ejhf.2587
Diederich T, Burdorf A, Pozehl B, Bowman S, Ferguson K, Holder K, et al. The role of a multidisciplinary heart failure clinic in optimization of guideline‐directed medical therapy: HF‐Optimize. Heart Lung 2023;57:95–101. https://doi.org/10.1016/j.hrtlng.2022.08.010
Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ‐5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010;8:13. https://doi.org/10.1186/1477‐7525‐8‐13
Van Wilder L, Rammant E, Clays E, Devleesschauwer B, Pauwels N, De Smedt D. A comprehensive catalogue of EQ‐5D scores in chronic disease: Results of a systematic review. Qual Life Res 2019;28:3153–3161. https://doi.org/10.1007/s11136‐019‐02300‐y
Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health‐related quality of life in patients with different diseases measured with the EQ‐5D‐5L: A systematic review. Front Public Health 2021;9:675523. https://doi.org/10.3389/fpubh.2021.675523
Peters M, Crocker H, Dummett S, Jenkinson C, Doll H, Fitzpatrick R. Change in health status in long‐term conditions over a one year period: A cohort survey using patient‐reported outcome measures. Health Qual Life Outcomes 2014;12:123. https://doi.org/10.1186/s12955‐014‐0123‐2
Brazier J, Longworth L. NICE DSU Technical Support Document 8: An introduction to the measurement and valuation of health for NICE submissions. London: National Institute for Health and Care Excellence (NICE); August; 2011.
Institute for Clinical and Economic Review. 2020–2023 Value Assessment Framework. January 31,2020. Boston, MA: ICER; 2020.